Raynaud's phenomenon (secondary)
Abstract
Introduction: Raynaud's phenomenon is episodic vasospasm of the peripheral vessels, causing pallor followed by cyanosis and redness with pain and sometimes paraesthesia, and, rarely, ulceration of the fingers and toes. It presents as episodic colour changes of the digits, usually in response to cold exposure or stress. The classic triphasic colour change is white (ischaemia), then blue (deoxygenation), then red (reperfusion). Raynaud's phenomenon can be primary (idiopathic) or secondary to several different conditions and causes. This review deals with secondary Raynaud's phenomenon.
Methods and outcomes: We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of self-help measures for secondary Raynaud's phenomenon? What are the effects of drug treatments for secondary Raynaud's phenomenon? We searched: Medline, Embase, The Cochrane Library, and other important databases up to May 2007 (BMJ Clinical Evidence reviews are updated periodically, please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).
Results: We found 25 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.
Conclusions: In this systematic review we present information relating to the effectiveness and safety of the following interventions: alpha-blockers; angiotensin-converting enzyme (ACE) inhibitors; angiotensin II receptor antagonists; antithrombotics/inhibitors of platelet aggregation; biofeedback; calcium channel blockers; endothelin-1 receptor anatagonists; glyceryl trinitrate (transdermal); hand exercises; inositol nicotinate; moxisylyte; nafitidrofuryl oxylate; phosphodiesterase inhibitors; prostaglandins (oral, intravenous); relaxation therapy; serotonin reuptake inhibitors SRIs; smoking cessation; and warming hands and feet.
Similar articles
-
Raynaud's phenomenon (secondary).BMJ Clin Evid. 2014 Oct 14;2014:1125. BMJ Clin Evid. 2014. PMID: 25322727 Free PMC article.
-
Raynaud's phenomenon (primary).BMJ Clin Evid. 2008 Dec 16;2008:1119. BMJ Clin Evid. 2008. PMID: 19445785 Free PMC article.
-
Raynaud's phenomenon (primary).BMJ Clin Evid. 2011 Mar 14;2011:1119. BMJ Clin Evid. 2011. PMID: 21401971 Free PMC article.
-
Raynaud's phenomenon (primary).BMJ Clin Evid. 2013 Oct 10;2013:1119. BMJ Clin Evid. 2013. PMID: 24112969 Free PMC article.
-
Calcium channel blockers for primary and secondary Raynaud's phenomenon.Cochrane Database Syst Rev. 2017 Dec 13;12(12):CD000467. doi: 10.1002/14651858.CD000467.pub2. Cochrane Database Syst Rev. 2017. PMID: 29237099 Free PMC article.
Cited by
-
A Multicenter Study of the Validity and Reliability of Responses to Hand Cold Challenge as Measured by Laser Speckle Contrast Imaging and Thermography: Outcome Measures for Systemic Sclerosis-Related Raynaud's Phenomenon.Arthritis Rheumatol. 2018 Jun;70(6):903-911. doi: 10.1002/art.40457. Epub 2018 Apr 23. Arthritis Rheumatol. 2018. PMID: 29457381 Free PMC article.
-
Evidence-based management of Raynaud's phenomenon.Ther Adv Musculoskelet Dis. 2017 Dec;9(12):317-329. doi: 10.1177/1759720X17740074. Epub 2017 Nov 20. Ther Adv Musculoskelet Dis. 2017. PMID: 29201156 Free PMC article. Review.
-
Management of Raynaud's phenomenon in systemic sclerosis-a practical approach.J Scleroderma Relat Disord. 2019 Jun;4(2):102-110. doi: 10.1177/2397198318823951. Epub 2019 Jan 28. J Scleroderma Relat Disord. 2019. PMID: 35382396 Free PMC article. Review.
-
The pathogenesis, diagnosis and treatment of Raynaud phenomenon.Nat Rev Rheumatol. 2012 Aug;8(8):469-79. doi: 10.1038/nrrheum.2012.96. Epub 2012 Jul 10. Nat Rev Rheumatol. 2012. PMID: 22782008 Review.
-
Raynaud's phenomenon.J Scleroderma Relat Disord. 2019 Jun;4(2):89-101. doi: 10.1177/2397198319826467. Epub 2019 Feb 13. J Scleroderma Relat Disord. 2019. PMID: 35382391 Free PMC article. Review.
References
-
- Wigley FM. Raynaud's phenomenon. N Eng J Med 2002;347:1001–1008. - PubMed
-
- Herrick AL. Pathogenesis of Raynaud's phenomenon. Rheumatol 2005;44:587–596. - PubMed
-
- Nihtyanova SI, Brough GM, Black CM, et al. Clinical burden of digital vasculopathy in limited and diffuse cutaneous systemic sclerosis. Ann Rheum Dis Available online at: http://ard.bmj.com/cgi/content/full/67/1/120 (last accessed 27 August 2010). - PubMed
-
- Stetter F, Kupper S. Autogenic training: a meta-analysis of clinical outcome studies. Applied Psychophysiol Biofeedback 2002;27:45–98. - PubMed
-
- Raynaud's Treatment Study Investigators: Comparison of sustained-release nifedipine and temperature biofeedback for treatment of primary Raynaud's phenomenon. Results from a randomized clinical trial with 1-year follow-up. Arch Intern Med 2000;160:1101–1108. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous